MARKET

DBVT

DBVT

DBV Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.99
+0.06
+0.60%
After Hours: 9.99 0 0.00% 16:00 02/27 EST
OPEN
9.64
PREV CLOSE
9.93
HIGH
10.04
LOW
9.54
VOLUME
800.07K
TURNOVER
--
52 WEEK HIGH
13.49
52 WEEK LOW
6.63
MARKET CAP
721.73M
P/E (TTM)
-3.0696
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DBVT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DBVT stock price target is 16.40 with a high estimate of 29.12 and a low estimate of 7.03.

EPS

DBVT News

More
  • DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020
  • GlobeNewswire · 3d ago
  • Ad Com set for DBV Tech peanut allergy therapy
  • seekingalpha · 6d ago
  • DBV Technologies Press Release Confirms FDA AdCom Panel For Viaskin Peanut Candidate As May 15, 2020
  • Benzinga · 6d ago
  • DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children
  • GlobeNewswire · 6d ago

Industry

Pharmaceuticals
-2.78%
Pharmaceuticals & Medical Research
-3.01%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About DBVT

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
More

Webull offers kinds of DBV Technologies SA stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.